Compare · NVO vs PLYX
NVO vs PLYX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Polaryx Therapeutics Inc. (PLYX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PLYX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 800.6x PLYX ($229.6M).
- Over the past year, NVO is down 34.2% and PLYX is down 86.0% - NVO leads by 51.8 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for PLYX).
- NVO has more recent analyst coverage (25 ratings vs 1 for PLYX).
- Company
- Novo Nordisk A/S
- Polaryx Therapeutics Inc.
- Price
- -
- -
- Market cap
- $183.82B
- $229.6M
- 1M return
- +13.32%
- -23.52%
- 1Y return
- -34.24%
- -85.99%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest PLYX
- Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
- Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
- Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
- Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
- Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
- Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
- Maxim Group initiated coverage on Polaryx Therapeutics with a new price target
- Chief Financial Officer Landis G. Michael bought $7,991 worth of shares (2,867 units at $2.79), increasing direct ownership by 1% to 228,225 units (SEC Form 4)
- Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial